Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

NASDAQ:ADAP

Adaptimmune Therapeutics plc

0.28

−0.58%

−0.02

Last Close

0.29

09/05 22:21

Market Cap

72.60M

Beta: 2.24

Volume Today

564.86K

Avg: 683.17K

PE Ratio

−1.68

PFCF: −2.03

name

homepage url

country

crunchbase url

employee count

sector

industry

revenue

Description

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics